Company
Genetic Signatures Limited
ASX:GSS
Molecular diagnostics company built on its proprietary 3base sample-chemistry platform, which converts non-methylated cytosines before amplification to reduce sequence complexity and allow highly multiplexed real-time PCR. It sells EasyScreen kits and the GS1 automated workflow to clinical laboratories for gastrointestinal (bacterial, viral, parasitic), respiratory, and vaccine-preventable pathogen detection, with customers in Australia, the UK, and the US. Longevity relevance is peripheral and indirect: the exposure is infectious disease testing infrastructure, not ageing biology, biological age measurement, or any geroscience intervention. It belongs in the universe on the diagnostics limb and on ASX listing, not on scientific proximity to healthspan. Nothing in its product line targets ageing mechanisms.
At a glance
- Listing
- ASX:GSS
- Category
- Diagnostics
- Headquarters
- Newtown, Sydney, NSW, Australia
- Market cap
- Approximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only.
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- On 2 July 2026, BCAL Diagnostics acquired a 10.2 percent stake (23,173,644 shares at 6.0 cents, A$1,390,119) in Genetic Signatures, framed as a strategic position in a complementary diagnostics company with existing PCR manufacturing, regulatory clearances, and distribution in Australia, the UK, and the US. The stake was taken against a weak backdrop: H1 FY26 revenue of about A$8.7 million (up 2.4 percent year on year) with the board conceding that US sales of its key commercialised product had fallen short of expectations, and the shares near 52-week lows. Source: Sharecafe, 2 July 2026, corroborated by Kalkine and an Investing.com H1 FY26 earnings call transcript.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:GSS |
| Secondary listing | None |
| Market cap | Approximately A$14 million, derived from the 2 July 2026 placement of 23,173,644 shares (10.2 percent) at 6.0 cents, implying about 227 million shares on issue. This is inferred from the transaction terms, not taken from a live exchange quote, so treat it as indicative only. |
| Status | Listed and trading |
Get in touch
Contact
- Address
- Newtown, Sydney, NSW, Australia
- Website
- www.geneticsignatures.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
On 2 July 2026, BCAL Diagnostics acquired a 10.2 percent stake (23,173,644 shares at 6.0 cents, A$1,390,119) in Genetic Signatures, framed as a strategic position in a complementary diagnostics company with existing PCR manufacturing, regulatory clearances, and distribution in Australia, the UK, and the US. The stake was taken against a weak backdrop: H1 FY26 revenue of about A$8.7 million (up 2.4 percent year on year) with the board conceding that US sales of its key commercialised product had fallen short of expectations, and the shares near 52-week lows. Source: Sharecafe, 2 July 2026, corroborated by Kalkine and an Investing.com H1 FY26 earnings call transcript.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Genetic Signatures: company site, 3base platform and EasyScreen product lines, registered office 7 Eliza Street, Newtown NSW 2042 · Genetic Signatures Limited
- BCAL Diagnostics Acquires Strategic Stake in Genetic Signatures · Sharecafe
- BCAL Diagnostics Acquires 10.2% Stake in Genetic Signatures for $1.39 Million · Kalkine
- Earnings call transcript: Genetic Signatures reports H1 FY26 results amid U.S. growth focus · Investing.com
- ASX Health Stocks: Genetic Signatures gets FDA approval for EasyScreen Gastrointestinal Parasite Detection Kit and GS1 workflow · Stockhead
Every entity profile on variis is sourced. Not investment advice.